<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3937">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530136</url>
  </required_header>
  <id_info>
    <org_study_id>C1 6201</org_study_id>
    <nct_id>NCT04530136</nct_id>
  </id_info>
  <brief_title>Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19</brief_title>
  <official_title>Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharming Technologies B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharming Technologies B.V.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC)&#xD;
      in patients admitted for stage II COVID-19 infection may reduce the risk of disease&#xD;
      progression, i.e. ALI requiring mechanical ventilation, or increase the chance of a faster&#xD;
      clinical improvement compared to SOC alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients fulfilling all eligibility criteria will be randomized in a 2:1 ratio in an&#xD;
      open-label controlled design to treatment with rhC1-INH in addition to SOC or SOC only&#xD;
      starting on day 0. The first rhC1-INH treatment will be administered on the same day and&#xD;
      continued for a total of 4 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Severity on the 7-Point WHO Ordinal Scale</measure>
    <time_frame>Assessed on each day after enrollment (worst status) with the use of the WHO Ordinal Scale and the score on day 7 will be analyzed stratified by its baseline value</time_frame>
    <description>The primary endpoint will be the disease severity on the 7-point WHO Ordinal Scale on day 7. This endpoint has been suggested by WHO for clinical trials in patients with COVID-19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>Daily until day 14</time_frame>
    <description>at least 2 points Ordinal Scale for Clinical Improvement, clinical severity will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive or non-invasive ventilation</measure>
    <time_frame>Daily until day 14.</time_frame>
    <description>Admission to ICU with invasive or non-invasive ventilation or death will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Lung Injury</measure>
    <time_frame>Daily until day 14.</time_frame>
    <description>Patients with ALI within 14 days after enrollment, PaO2/FiO2 will be determined daily. This is only relevant for patients with arterial blood gas sampling performed in the ICU or rarely in the medical unit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Confirmed Coronavirus Disease</condition>
  <arm_group>
    <arm_group_label>Ruconest</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SOC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruconest</intervention_name>
    <description>Patients will be randomized to Ruconest or Standard of Care</description>
    <arm_group_label>Ruconest</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-85 years,&#xD;
&#xD;
          -  Admitted to the hospital because of confirmed positive SARS-CoV-2 (COVID-19&#xD;
             infection).&#xD;
&#xD;
          -  Evidence of pulmonary involvement on CT scan or X-Ray of the chest,&#xD;
&#xD;
          -  Symptom onset within the previous 10 days AND at least one additional risk factor for&#xD;
             progression to mechanical ventilation: 1) arterial hypertension, 2) &gt;50 years, 3)&#xD;
             obesity (BMI&gt;30.0 kg/m2), 4) history of cardiovascular disease, 5) chronic pulmonary&#xD;
             disease, 7) chronic renal disease, 6) C-reactive protein of &gt;35mg/L, 7) oxygen&#xD;
             saturation at rest in ambient air of &lt;94%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to the class of drugs under study (C1 esterase inhibitor);&#xD;
&#xD;
          -  History or suspicion of allergy to rabbits;&#xD;
&#xD;
          -  Women who are of childbearing potential and not using methods of contraception during&#xD;
             the entire study period;&#xD;
&#xD;
          -  Pregnant or breastfeeding females or has a positive serum β-human chorionic&#xD;
             gonadotropin (hCG) pregnancy test at screening;&#xD;
&#xD;
          -  Chronic liver disease (any Child-Pugh score B or C);&#xD;
&#xD;
          -  Currently admitted to an ICU or expected admission within the next 24 hours; and&#xD;
&#xD;
          -  Currently receiving invasive or non-invasive ventilation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Bernstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anurag Relan, MD</last_name>
    <phone>+31 71 5247 400</phone>
    <email>medical-information@pharming.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leisa Waynick, BSBA</last_name>
    <phone>908-947-6291</phone>
    <email>L.Waynick@pharming.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhama Reyes, BSN RN</last_name>
      <phone>201-447-8453</phone>
      <email>rreyes2@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Evan Leibowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

